Galderma Group AG (GALDY)

Market Cap	46.72B +54.0%
Revenue (ttm)	5.24B +18.0%
Net Income	613.00M +165.4%
EPS	2.58 +166.0%
Shares Out	n/a
PE Ratio	76.21
Forward PE	43.44
Dividend	0.02 (0.06%)
Ex-Dividend Date	Apr 28, 2025

Volume	21,464
Average Volume	151,342
Open	39.63
Previous Close	40.52
Day's Range	38.30 - 40.41
52-Week Range	17.27 - 42.93
Beta	n/a
RSI	48.57
Earnings Date	Mar 5, 2026

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 7,676
• Stock Exchange: OTCMKTS
• Ticker Symbol: GALDY

Financial Performance

In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.